Base4

Executive Summary

Base4 Biotechnology, founded in 2018 in San Diego, is a private biotech company leveraging an AI-enhanced, structure-based discovery platform to develop RNA-modulating small molecule drugs. Originally launched as Nymirum in 2009, the company targets previously untreatable diseases by modulating RNA function, a novel therapeutic approach with broad applicability. Its platform combines computational modeling and machine learning to identify small molecules that bind to RNA with high specificity, enabling the modulation of disease-relevant RNA targets. This technology positions Base4 to address intractable conditions in neurology, oncology, neuromuscular disorders, and rare diseases, where traditional protein-targeting drugs have limited success. The company's focus on RNA modulation places it at the forefront of a rapidly advancing field, with potential to unlock new classes of therapeutics for patients with high unmet medical needs. Base4's proprietary platform aims to accelerate drug discovery by reducing timelines and improving hit rates, making it an attractive player in the biotech landscape.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate nomination for neurology program60% success
• Q4 2026IND filing for oncology program50% success
• Q2 2026Preclinical data presentation at major conference70% success